Ex-Sanofi Gen­zyme chief David Meek­er hops to a new biotech CEO post, this time fo­cus­ing on quick leap to com­mer­cial­iza­tion

Six months af­ter Rhythm Phar­ma­ceu­ti­cals CEO Kei­th Gottes­di­ener an­nounced plans to ex­it on the heels of the biotech’s first FDA fil­ing, the Boston-based biotech has found the ex­pe­ri­enced bio­phar­ma CEO they want to lead their hoped-for tran­si­tion in­to com­mer­cial­iza­tion.

Ex-Sanofi Gen­zyme chief David Meek­er — who jumped from his last job as CEO of KSQ less than 2 weeks ago — has now moved on to Rhythm.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER